106 related articles for article (PubMed ID: 15848720)
1. C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients.
Barten MJ; Rahmel A; Garbade J; Richter M; Bittner HB; Dhein S; Mohr FW; Gummert JF
Transplant Proc; 2005 Mar; 37(2):1360-1. PubMed ID: 15848720
[TBL] [Abstract][Full Text] [Related]
2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
Barten MJ; Rahmel A; Garbade J; Bold A; Bittner HB; Dhein S; Mohr FW; Gummert JF
Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162
[TBL] [Abstract][Full Text] [Related]
4. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
[TBL] [Abstract][Full Text] [Related]
5. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
[TBL] [Abstract][Full Text] [Related]
6. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function.
Barten MJ; Shipkova M; Bartsch P; Dhein S; Streit F; Tarnok A; Armstrong VW; Mohr FW; Oellerich M; Gummert JF
Ther Drug Monit; 2005 Apr; 27(2):123-31. PubMed ID: 15795640
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.
Gregoor PJ; de Sévaux RG; Hené RJ; Hesse CJ; Hilbrands LB; Vos P; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 1999 Nov; 68(10):1603-6. PubMed ID: 10589962
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
Ghio L; Ferraresso M; Viganò SM; Ginevri F; Perfumo F; Gianoglio B; Murer L; Zacchello G; Dello Strologo L; Cardillo M; Tirelli S; Valente U; Edefonti A
Transplant Proc; 2005 Mar; 37(2):856-8. PubMed ID: 15848555
[TBL] [Abstract][Full Text] [Related]
11. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
Klupp J; van Gelder T; Dambrin C; Regieli JJ; Boeke K; Billingham ME; Morris RE
J Heart Lung Transplant; 2004 Mar; 23(3):334-51. PubMed ID: 15019644
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of T-cell function for monitoring immunosuppression.
Barten MJ; Tarnok A; Garbade J; Bittner HB; Dhein S; Mohr FW; Gummert JF
Cell Prolif; 2007 Feb; 40(1):50-63. PubMed ID: 17227295
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
16. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts.
Grinyó JM; Cruzado JM; Millán O; Caldés A; Sabaté I; Gil-Vernet S; Serón D; Brunet M; Campistol JM; Torras J; Martorell J
Transplantation; 2004 Nov; 78(9):1400-3. PubMed ID: 15548982
[TBL] [Abstract][Full Text] [Related]
17. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
[TBL] [Abstract][Full Text] [Related]
18. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
Sheshgiri R; Gustafsson F; Sheedy J; Rao V; Ross HJ; Delgado DH
J Heart Lung Transplant; 2009 Nov; 28(11):1193-7. PubMed ID: 19783164
[TBL] [Abstract][Full Text] [Related]
19. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.
Smak Gregoor PJ; van Gelder T; Hesse CJ; van der Mast BJ; van Besouw NM; Weimar W
Nephrol Dial Transplant; 1999 Mar; 14(3):706-8. PubMed ID: 10193823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
